VERAPAMIL SLOW RELEASE
Reversible Cerebral Vasoconstriction Syndrome
Johns Hopkins UniversitySmall moleculePhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Reversible Cerebral Vasoconstriction Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Nimodipine Johns Hopkins University | Phase 4 | BB |
Onabotulinum Toxin A University of Alberta | Phase 1 | CC |
Same molecule, other indications
VERAPAMIL SLOW RELEASE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →